Semaglutide (Ozempic, Wegovy): how it works, what the trials show, side effects and blood tests

The weekly GLP-1 drug behind Ozempic and Wegovy: what the trials found, how often the side effects hit, what happens when you stop, and the lab results it moves.

Reviewed by LifeFrom’s medical AIPublished November 21, 2026 · 11 min
Ask AI about this pageChatGPTClaudePerplexity
The distinctions
  1. 01
    Semaglutide's effects on weight and labs last as long as the weekly dose does

    Semaglutide lowers appetite, weight, A1C, triglycerides and blood pressure while it is in the body, and those changes fade once it is gone. In STEP 4, people who switched to placebo after 20 weeks regained 6.9% of their body weight over the next 48 weeks, while people who stayed on semaglutide lost a further 7.9% 3. In the STEP 1 extension, people had regained about two-thirds of their lost weight a year after stopping, and their gains in blood pressure, blood sugar and cholesterol had largely gone 4. So a good A1C or triglyceride result on semaglutide shows the drug is working, while the underlying condition is still there. Plan any change or stop with the prescriber, and expect to recheck the same blood tests a few months later.

Semaglutide works for as long as you take it. That explains why weight returns after stopping, and why A1C (the 3-month blood sugar average) and triglycerides (blood fats) improve on treatment and drift back off it. The same molecule sits in Ozempic, Wegovy, Rybelsus and the Wegovy pill. In trials it lowered weight, blood sugar, heart events and kidney events, and stomach side effects were the most common problem.

What semaglutide is and how it works

Semaglutide is a lab-made version of GLP-1 (glucagon-like peptide-1), a hormone the gut releases after a meal. Your own GLP-1 lasts only a few minutes in the blood before an enzyme called DPP-4 breaks it down. Semaglutide shares 94% of its sequence with human GLP-1 5, with two changes that keep it around: one swapped amino acid that DPP-4 cannot cut, and a fatty side chain that sticks to albumin, the main protein in blood. Those changes stretch semaglutide's half-life (the time it takes for half a dose to clear) to about a week 5, which is why one injection covers seven days. Medicines in this family are called GLP-1 receptor agonists, meaning drugs that switch on the same receptor as the natural hormone.

  • In the pancreas, semaglutide raises insulin only when blood sugar is high and lowers glucagon, the hormone that tells the liver to release sugar. Because the insulin effect depends on glucose, semaglutide on its own rarely causes low blood sugar; taken with insulin or a sulfonylurea (an older diabetes pill such as glipizide that pushes insulin out whatever the blood sugar) it can 5.
  • In the stomach, semaglutide slows emptying, so a meal stays longer and fullness lasts.
  • In the brain, semaglutide acts on appetite centres, so hunger and food cravings fall and people eat less.

The weight loss on semaglutide comes from eating less, because the drug turns appetite down. The slowed stomach is also why most side effects sit in the gut. Semaglutide is used for type 2 diabetes, for weight loss in obesity, and now for fatty liver with scarring.

How Ozempic, Wegovy, Rybelsus and the Wegovy pill differ

Ozempic and Wegovy are the same molecule in the same kind of weekly pen. Wegovy climbs to a higher dose (2.4 mg a week, or 7.2 mg as Wegovy HD, against Ozempic's 2 mg) and carries the weight, heart and liver approvals; Ozempic is labelled for type 2 diabetes and the heart and kidney risks that come with it 7. Rybelsus and the Wegovy pill are daily tablets of the same drug, which needs far larger doses by mouth because little survives the stomach.

BrandFormHighest labelled doseFDA-approved forFirst approved
OzempicWeekly injection2 mgBlood sugar in type 2 diabetes; lower heart attack, stroke and cardiovascular death risk in type 2 diabetes with heart disease; lower kidney failure risk in type 2 diabetes with chronic kidney disease (added 2025) 72017
RybelsusDaily tablet14 mg (original tablet)Blood sugar in type 2 diabetes; lower heart attack, stroke and cardiovascular death risk in type 2 diabetes at high heart risk (added 2025) 82019
Wegovy injectionWeekly injection2.4 mgChronic weight management from age 12; lower heart attack, stroke and cardiovascular death risk in adults with heart disease and overweight or obesity (2024); MASH, fatty liver with inflammation and moderate to advanced scarring (2025) 52021
Wegovy HDWeekly injection7.2 mgFurther weight loss and keeping it off in some adults with obesity 21March 2026
Wegovy pillDaily tablet25 mgWeight loss and keeping it off in adults 20December 2025

What the trials showed, including the misses

TrialWho took partWhat happened
STEP 1, 68 weeks 11,961 adults with obesity or overweight, no diabetesAverage weight loss 14.9% on weekly 2.4 mg, 2.4% on placebo
OASIS 4, 64 weeks 12307 adults with obesity or overweight, no diabetesDaily 25 mg pill: average weight loss 13.6%, against 2.2% on placebo
STEP UP, 72 weeks 131,407 adults with obesity, no diabetesWeekly 7.2 mg: 18.7% average weight loss, against 15.6% on 2.4 mg and 3.9% on placebo
SELECT, about 40 months 217,604 adults with heart disease and overweight or obesity, no diabetesHeart attack, stroke or cardiovascular death in 6.5% against 8.0% on placebo, a 20% lower risk
SUSTAIN-6, 2 years 113,297 people with type 2 diabetes at high heart risk26% fewer heart attacks, strokes and cardiovascular deaths, but more diabetic eye complications (3.0% against 1.8%)
STEP 4, 48 weeks after a 20-week start 3803 adults who had already lost weight on semaglutideStaying on it: a further 7.9% lost. Switching to placebo: 6.9% regained
FLOW, median 3.4 years 93,533 people with type 2 diabetes and chronic kidney diseaseMajor kidney events, including kidney failure, 24% less likely
ESSENCE, 72 weeks 10800 people with MASH and moderate to advanced liver scarringLiver inflammation cleared without worse scarring in 62.9% against 34.3% on placebo
EVOKE and EVOKE+, 2 years 193,808 people with early Alzheimer's diseaseOral semaglutide did not slow decline in memory and thinking

Results varied widely in STEP 1: about a third of people on semaglutide lost 20% or more of their body weight, while about 1 in 7 lost less than 5% 1. No test predicts in advance which group a person will land in.

How a course of semaglutide starts

Every semaglutide label starts low on purpose. Nausea and vomiting track the dose increases, so each step is held for 4 weeks before the next. The prescriber sets the pace and can hold a step for longer, or stay on a lower dose, when side effects are rough. The table shows the schedule printed in the Wegovy label; it is for reading a prescription, not for setting your own dose. Ozempic uses different steps (0.25, 0.5, 1 and then 2 mg, each after at least 4 weeks) 7, and Wegovy HD adds a 7.2 mg step for some adults already on 2.4 mg 21.

WeeksWegovy weekly injection on the label 5
1 to 40.25 mg (a starting step, not a treatment dose)
5 to 80.5 mg
9 to 121 mg
13 to 161.7 mg
17 onward2.4 mg maintenance, or 1.7 mg if 2.4 mg is not tolerated

Taking a daily semaglutide pill

On wakingBest
Rest of the day
With foodEmpty stomach, swallowed with no more than 4 oz (about 120 mL) of plain water
How oftenOnce a day, then wait at least 30 minutes before food, drinks or other pills
Space ~2h fromBreakfastCoffee and teaOther morning pills
From the Rybelsus US prescribing information 8; the Wegovy pill follows similar rules. Food or extra water in the stomach cuts how much semaglutide gets absorbed. Your own pharmacy leaflet comes first.

How long semaglutide takes to work

  • First few weeks: appetite usually falls early, often on the starting doses, well before weight loss is obvious on the scale.
  • About 3 months: A1C reflects roughly 3 months of blood sugar, so the full drop shows on a test at about that point.
  • Months 3 to 15: most of the weight comes off in this stretch; in STEP 1 the average weight curve flattened from about week 60 1.

Side effects and how common they are

Side effectAdults on WegovyAdults on placebo
Nausea44%16%
Diarrhea30%16%
Vomiting24%6%
Constipation24%11%
Tummy pain20%10%

These are the typical GLP-1 side effects, and the figures come from the Wegovy weight trials 5. Stomach side effects usually start or worsen in the days after a dose increase and ease over the following weeks. Smaller meals, stopping at the first sign of fullness and going easy on fatty food are the usual first steps, with more fiber, such as psyllium, and plenty of fluids for constipation. Semaglutide also raises resting heart rate by 1 to 4 beats a minute on average 5.

Serious risks and who should not take semaglutide

  • Thyroid: semaglutide carries a boxed warning, the FDA's strongest label warning, because it caused tumors of the thyroid's C-cells (the cells that make calcitonin) in preclinical studies; whether that happens in people is unknown. Anyone with a personal or family history of medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2, an inherited condition that causes gland tumors) should not take it 5.
  • Pancreatitis, gallbladder disease and gallstones, and kidney injury from dehydration after vomiting or diarrhea are listed warnings 5.
  • Diabetic eye disease: in SUSTAIN-6, people with type 2 diabetes on semaglutide had more retinopathy complications, 3.0% against 1.8%, most often when blood sugar fell fast from a high start 11.
  • NAION, a sudden loss of blood flow to the optic nerve: the European Medicines Agency concluded in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 users 15.
  • Sedation and anesthesia: food can stay in a slowed stomach and be breathed in, so the label says to tell the team before any procedure 5.
  • Pregnancy: semaglutide is not used in pregnancy, and the label advises stopping at least 2 months before a planned pregnancy, because semaglutide takes weeks to leave the body 5.

Medicines and habits that interact with semaglutide

  • Insulin and sulfonylureas (such as glipizide): the combination can cause low blood sugar, so prescribers often lower those doses when semaglutide starts 5.
  • Pills that need steady absorption: a slower stomach can change how other medicines are absorbed. The Rybelsus label reports higher levothyroxine levels when the two are taken together 8, so your prescriber may recheck your TSH a few weeks after starting.
  • Other GLP-1 drugs, including tirzepatide: the label says semaglutide should not be used together with another GLP-1 receptor agonist 5.
  • Alcohol: adds to nausea and dehydration, and with insulin or a sulfonylurea adds to the low blood sugar risk.

Muscle loss, protein and eating less

Some of the weight lost on semaglutide is muscle and other lean tissue. In a STEP 1 substudy that measured body composition with DEXA scans, lean mass made up roughly 40% of the weight lost, although the share of the body that was lean rose because fat fell faster 1. Resistance training and eating enough protein help hold on to muscle while eating less; the protein calculator gives a daily target from body weight.

CalculatorProtein calculatorTurns your body weight into a daily protein range, useful when semaglutide shrinks your appetiteWork it out

Eating a lot less for months also leaves less room for iron-rich and B12-rich foods. Ferritin and B12 are two results worth asking the prescriber about if appetite has dropped sharply, and B12 doubly so for anyone also on metformin, which can lower B12 over years; B12 deficiency covers the symptoms.

Blood tests on semaglutide: before you start and what changes

In STEP 1, semaglutide improved A1C, fasting glucose, triglycerides, blood pressure, waist size and C-reactive protein compared with placebo 1. Those changes are easiest to read against a starting point: a baseline A1C, lipid panel, liver panel and kidney panel before the first dose, A1C again at about 3 months, and ferritin and B12 if you are eating far less than before. Bring the old and new results to the same appointment so the prescriber can compare them.

ResultUsual change on semaglutideWhen to raise it with the prescriber
A1C and fasting glucoseDown; the A1C change shows within about 3 months 1A rising A1C on a steady dose
TriglyceridesDown 1A rise, which is not the expected direction
ALT and GGT (liver enzymes)May fall as liver fat fallsA rise with yellow skin or upper right tummy pain
hs-CRP (inflammation)Down 1Rarely matters on its own
Creatinine and eGFR (kidney filtration)Usually stableCreatinine up and eGFR down after vomiting or diarrhea, a sign of dehydration 5
Lipase and amylaseCan rise with no pancreatitis 5Straight away with severe tummy pain spreading to the back
Ferritin and B12May drift down when eating far lessA low result, or new tiredness, pins and needles or breathlessness

For the panels themselves, liver enzymes explained and kidney function explained go line by line. The semaglutide label lists raised lipase and amylase, both pancreas enzymes, among its lab findings, and says their meaning is unknown without other signs or symptoms of pancreatitis 5. A high lipase result on a routine panel, with no tummy pain, usually leads to a repeat test; the same result with severe pain spreading to the back needs urgent care. A GLP-1 blood test measures your own hormone; it is a research test and does not show how much semaglutide is in the body or whether the dose is right.

Free, no accountRead your blood testGot an A1C, lipid or liver panel back since starting semaglutide? Read every line of it, free.Read my results

What happens when you stop semaglutide

Weight splits apart when semaglutide stops
Stayed on semaglutideSwitched to placebo at week 20
% change in body weightWk 048121620283644526068Week 20: half switch to placebo
Illustrative shape based on STEP 4, not individual data. Everyone took semaglutide for 20 weeks; over the next 48 weeks, people who stayed on it lost a further 7.9% of body weight, while people switched to placebo regained 6.9% of their week-20 weight, ending about 5% below where they started 3.

In the STEP 1 extension, people who stopped at 68 weeks had regained about two-thirds of the weight they had lost a year later, and their improvements in blood pressure, A1C and cholesterol had largely gone too 4. The trial's authors drew a plain conclusion.

Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.Wilding et al., STEP 1 trial extension, Diabetes Obes Metab 2022 4

Anyone thinking of stopping or tapering does better planning it with the prescriber and rechecking A1C and lipids a few months after; how to read your lipid panel explains each line.

About 2/3of the weight lost on semaglutide had come back one year after stoppingSTEP 1 extension, 327 adults 4

Compounded and online semaglutide

During the shortage that began in 2022, US pharmacies were allowed to compound copies of semaglutide. The FDA declared the semaglutide shortage resolved on 21 February 2025, and the grace periods ended on 22 April 2025 for local compounding pharmacies and 22 May 2025 for large-scale outsourcing facilities 16. Some telehealth sellers still offer compounded semaglutide under narrower rules, and the FDA does not review these products before sale.

This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.US Food and Drug Administration, on compounded GLP-1 drugs 6

The FDA also warns that some compounded products contain semaglutide sodium or semaglutide acetate, salt forms that are different active ingredients from the approved drug, and that it knows of no lawful basis for compounding with them 6. The agency has received reports of adverse events, some needing hospital care, from people measuring and injecting the wrong dose of compounded semaglutide 6. Approved Ozempic and Wegovy come in prefilled pens that deliver a set dose; a vial and syringe measured in units is a compounded format, and the mg doses on this page do not convert directly to units on a compounded vial. If you have injected more than intended, or have severe vomiting, cannot keep fluids down, or feel faint or confused after a dose, get medical help the same day.

Semaglutide vs tirzepatide and the next drugs

Tirzepatide (Mounjaro, Zepbound) acts on the GLP-1 receptor and a second gut-hormone receptor, GIP. In SURMOUNT-5, the first head-to-head weight trial, 751 adults on tirzepatide lost an average 20.2% of body weight at 72 weeks against 13.7% on semaglutide 14. Newer drugs add more hormone targets or swap the injection for a pill; the retatrutide vs semaglutide comparison sets out the triple-hormone shot against semaglutide in numbers.

Link · New England Journal of Medicine, 2025Tirzepatide as compared with semaglutide for the treatment of obesityThe SURMOUNT-5 trial: 751 adults with obesity and no diabetes, randomised to tirzepatide or semaglutide for 72 weeks.nejm.org
Free, no accountDrop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.
Citations
  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
  3. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
  4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
  5. Novo Nordisk. Wegovy (semaglutide) injection, US prescribing information. Revised 2025.
  6. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
  7. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information.
  8. Novo Nordisk. Rybelsus (semaglutide) tablets, US prescribing information.
  9. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
  10. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089-2099.
  11. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
  12. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087.
  13. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963.
  14. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
  15. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 2025.
  16. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025.
  17. US Food and Drug Administration. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. January 2024.
  18. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024.
  19. Novo Nordisk. Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. Company announcement, 24 November 2025.
  20. Novo Nordisk. FDA approves oral Wegovy pill. Press release, 22 December 2025.
  21. US Food and Drug Administration. FDA approves fourth product under National Priority Voucher program, higher dose semaglutide. 19 March 2026.

Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.